Meeting
2012 Breast Cancer Symposium
Single-institution experience with neoadjuvant chemotherapy for metaplastic breast cancer (MBC).
Authors
Anna Kaminsky
University of Pittsburgh Medical Center
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session B
Track
Survivorship and Health Policy,Systemic Therapy,Local/Regional Therapy
Sub Track
Triple-Negative
Citation
J Clin Oncol 30, 2012 (suppl 27; abstr 140)
DOI
10.1200/jco.2012.30.27_suppl.140
Abstract #
140
Poster Bd #
C16
Abstract Disclosures
Similar Posters
Poster
2011 ASCO Annual Meeting
Bcl2 as a surrogate prognostic and predictive marker in triple-negative breast cancer.
First Author: T. M. A. Abdel-Fatah
Poster
2017 ASCO Annual Meeting
Breast conservation after neoadjuvant chemotherapy for triple-negative breast cancer: Surgical results from an international randomized trial (BrighTNess).
First Author: Mehra Golshan
Poster
2024 ASCO Annual Meeting
Ten-year outcomes of targeted axillary surgery after neoadjuvant chemotherapy in breast cancer.
First Author: Jeeyeon Lee
Poster
2023 ASCO Annual Meeting
Association between genomic alterations and response of triple-negative breast cancers (TNBC) to talimogene laherparepvec (TVEC) in combination with neoadjuvant chemotherapy (NACT).
First Author: Hatem Hussein Soliman